Antiviral treatment of chronic hepatitis B virus (HBV) infections.

Article Details

Citation

Copy to clipboard

De Clercq E, Ferir G, Kaptein S, Neyts J

Antiviral treatment of chronic hepatitis B virus (HBV) infections.

Viruses. 2010 Jun;2(6):1279-305. doi: 10.3390/v2061279. Epub 2010 May 31.

PubMed ID

21994680 [ View in PubMed

]

Abstract

While 25 compounds have been formally licensed for the treatment of HIV infection (AIDS), only seven licensed products are currently available for the treatment of chronic hepatitis B virus (HBV) infection: interferon-alpha, pegylated interferon-alpha, lamivudine, adefovir (dipivoxil), entecavir, telbivudine and tenofovir (disoproxil fumarate). In contrast to the treatment of HIV infections where the individual drugs are routinely used in combination, for the treatment of chronic HBV infection the individual drugs are generally used in monotherapy. In principle, combination drug therapy should allow reducing the likelihood of drug-resistant development.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Tenofovir disoproxil	DNA polymerase/reverse transcriptase	Protein	HBV-D	Unknown	Inhibitor	Details